FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133176465> ?p ?o ?g. }

• W2133176465 endingPage "ii117" @default.
• W2133176465 startingPage "ii117" @default.
• W2133176465 abstract "Introduction: Molecular targeted therapy has made great progress in the treatment of gastric cancer. This paper reports the outcome of a phase III clinical study of apatinib, as an oral small molecular of VEGFR-2 tyrosine kinase inhibitor, in the treatment of patients with advanced gastric cancer who prior failure to second-line chemotherapy. This study may provide a new treatment options and leading a new hope for these patients. Methods: This is a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Apatinib or matching placebo, 850 mg, po, qd, 28 days as one cycle. Primary outcomes were overall survival. Study randomization was centralized and stratified according to the number of metastatic sites (≤2 or >2). Planned to enroll 270 cases: 180 of apatinib and 90 of placebo. This trial was registered with ClinicalTrials.gov, number NCT01512745. Results: The patient baseline characteristics were similar in two arms in regards to age, history of the disease, gender, ECOG scores, number of metastatic sites, pathological grading, clinical stage and therapy history (P > 0.05). As to efficacy, median overall survival (mOS) was significantly prolonger in the apatinib group compared with in the placebo group (195 days versus 140 days; HR= 0.71; 95% CI (0.54 ∼ 0.94); P < 0.016). Median progression-free survival (mPFS) was also prolonged in the apatinib group compared with the placebo group (78 days versus 53 days, HR = 0.44, 95% CI (0.33 ∼ 0.61), P < 0.0001). The objective response rates (ORR) of apatinib group and placebo group were 2.84% and 0.00% respectively. As to safety, treatment of apatinib group was generally well tolerated. Most of the adverse reactions could be managed by dose interruptions or reductions. Grade 3/4 adverse reactions that occurred in more than 2% of patients were hypertension, hand-and-foot syndrome, proteinuria, fatigue, anorexia, elevated aminotransferase. Conclusion: This study further confirmed the efficacy and safety of apatinib in patients with advanced gastric cancer. 850 mg, qd is the recommended dose for clinical use." @default.
• W2133176465 created "2016-06-24" @default.
• W2133176465 creator A5006423482 @default.
• W2133176465 creator A5006424190 @default.
• W2133176465 creator A5016456840 @default.
• W2133176465 creator A5017251382 @default.
• W2133176465 creator A5019131703 @default.
• W2133176465 creator A5020172186 @default.
• W2133176465 creator A5028256441 @default.
• W2133176465 creator A5031981304 @default.
• W2133176465 creator A5032375996 @default.
• W2133176465 creator A5033431630 @default.
• W2133176465 creator A5037658093 @default.
• W2133176465 creator A5038304016 @default.
• W2133176465 creator A5040769857 @default.
• W2133176465 creator A5044962165 @default.
• W2133176465 creator A5048349862 @default.
• W2133176465 creator A5050979366 @default.
• W2133176465 creator A5055506054 @default.
• W2133176465 creator A5055583404 @default.
• W2133176465 creator A5055746720 @default.
• W2133176465 creator A5057769470 @default.
• W2133176465 creator A5058178201 @default.
• W2133176465 creator A5059380001 @default.
• W2133176465 creator A5062179244 @default.
• W2133176465 creator A5068044246 @default.
• W2133176465 creator A5070745750 @default.
• W2133176465 creator A5071263487 @default.
• W2133176465 creator A5073986209 @default.
• W2133176465 creator A5078303906 @default.
• W2133176465 creator A5080944719 @default.
• W2133176465 creator A5081853954 @default.
• W2133176465 creator A5082486656 @default.
• W2133176465 creator A5087475349 @default.
• W2133176465 creator A5087661837 @default.
• W2133176465 date "2014-06-01" @default.
• W2133176465 modified "2023-10-17" @default.
• W2133176465 title "Phase III Study of Apatinib in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial" @default.
• W2133176465 doi "https://doi.org/10.1093/annonc/mdu193.29" @default.
• W2133176465 hasPublicationYear "2014" @default.
• W2133176465 type Work @default.
• W2133176465 sameAs 2133176465 @default.
• W2133176465 citedByCount "1" @default.
• W2133176465 countsByYear W21331764652018 @default.
• W2133176465 crossrefType "journal-article" @default.
• W2133176465 hasAuthorship W2133176465A5006423482 @default.
• W2133176465 hasAuthorship W2133176465A5006424190 @default.
• W2133176465 hasAuthorship W2133176465A5016456840 @default.
• W2133176465 hasAuthorship W2133176465A5017251382 @default.
• W2133176465 hasAuthorship W2133176465A5019131703 @default.
• W2133176465 hasAuthorship W2133176465A5020172186 @default.
• W2133176465 hasAuthorship W2133176465A5028256441 @default.
• W2133176465 hasAuthorship W2133176465A5031981304 @default.
• W2133176465 hasAuthorship W2133176465A5032375996 @default.
• W2133176465 hasAuthorship W2133176465A5033431630 @default.
• W2133176465 hasAuthorship W2133176465A5037658093 @default.
• W2133176465 hasAuthorship W2133176465A5038304016 @default.
• W2133176465 hasAuthorship W2133176465A5040769857 @default.
• W2133176465 hasAuthorship W2133176465A5044962165 @default.
• W2133176465 hasAuthorship W2133176465A5048349862 @default.
• W2133176465 hasAuthorship W2133176465A5050979366 @default.
• W2133176465 hasAuthorship W2133176465A5055506054 @default.
• W2133176465 hasAuthorship W2133176465A5055583404 @default.
• W2133176465 hasAuthorship W2133176465A5055746720 @default.
• W2133176465 hasAuthorship W2133176465A5057769470 @default.
• W2133176465 hasAuthorship W2133176465A5058178201 @default.
• W2133176465 hasAuthorship W2133176465A5059380001 @default.
• W2133176465 hasAuthorship W2133176465A5062179244 @default.
• W2133176465 hasAuthorship W2133176465A5068044246 @default.
• W2133176465 hasAuthorship W2133176465A5070745750 @default.
• W2133176465 hasAuthorship W2133176465A5071263487 @default.
• W2133176465 hasAuthorship W2133176465A5073986209 @default.
• W2133176465 hasAuthorship W2133176465A5078303906 @default.
• W2133176465 hasAuthorship W2133176465A5080944719 @default.
• W2133176465 hasAuthorship W2133176465A5081853954 @default.
• W2133176465 hasAuthorship W2133176465A5082486656 @default.
• W2133176465 hasAuthorship W2133176465A5087475349 @default.
• W2133176465 hasAuthorship W2133176465A5087661837 @default.
• W2133176465 hasBestOaLocation W21331764651 @default.
• W2133176465 hasConcept C121608353 @default.
• W2133176465 hasConcept C126322002 @default.
• W2133176465 hasConcept C141071460 @default.
• W2133176465 hasConcept C142724271 @default.
• W2133176465 hasConcept C143998085 @default.
• W2133176465 hasConcept C168563851 @default.
• W2133176465 hasConcept C204243189 @default.
• W2133176465 hasConcept C204787440 @default.
• W2133176465 hasConcept C27081682 @default.
• W2133176465 hasConcept C2776694085 @default.
• W2133176465 hasConcept C2780668389 @default.
• W2133176465 hasConcept C2780739268 @default.
• W2133176465 hasConcept C31760486 @default.
• W2133176465 hasConcept C535046627 @default.
• W2133176465 hasConcept C71924100 @default.
• W2133176465 hasConcept C90924648 @default.
• W2133176465 hasConceptScore W2133176465C121608353 @default.
• W2133176465 hasConceptScore W2133176465C126322002 @default.
• W2133176465 hasConceptScore W2133176465C141071460 @default.

• next